extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
6be17a893b
commit
e5951f3fc0
6 changed files with 45 additions and 5 deletions
|
|
@ -113,6 +113,12 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl
|
|||
|
||||
International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits are comprehensively accounted for, with T2D-related savings ($892M) exceeding obesity-related costs ($205M). This challenges the universal 'inflationary through 2035' framing by demonstrating that payer-level economics under risk-bearing arrangements can diverge from system-level cost impact.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
|
|||
|
||||
Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Medicare modeling quantifies multi-organ protection value: $14,431/subject in avoided T2D costs, $2,074/subject in avoided CKD costs, $1,512/subject in avoided CV event costs. Over 10 years, 38,950 cardiovascular events avoided and 6,180 deaths prevented, with per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -46,6 +46,12 @@ SELECT trial economic model shows $2,074 per-subject lifetime savings from avoid
|
|||
|
||||
In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Medicare modeling shows CKD-related savings of $2,074 per subject treated, which is smaller than T2D-related savings ($14,431/subject) but still material. The 10-year window captures dialysis delay benefits but may underestimate lifetime value since dialysis costs compound over decades.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -43,6 +43,12 @@ The composition of spending shifts dramatically: less on chronic disease managem
|
|||
|
||||
The Medicare semaglutide analysis provides a boundary condition: when payment is integrated and multi-indication benefits compound, prevention CAN bend the cost curve down for specific payers. However, this requires: (1) single entity bearing costs and capturing savings, (2) multi-indication efficacy across high-cost conditions, (3) sufficient persistence to realize benefits. The system-level curve may still bend up while risk-bearing integrated payers see net savings—a payment structure divergence.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Semaglutide demonstrates the mechanism: even when a single treatment saves money for a unified payer ($715M Medicare savings over 10 years), this requires comprehensive multi-indication use that increases total treatment volume. The 'cost curve bends up' claim holds at system level even as individual payer economics can be favorable under risk-bearing arrangements.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -1,7 +1,7 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md",
|
||||
"filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-under-unified-payer.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
|
|
@ -13,12 +13,12 @@
|
|||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:set_created:2026-03-18"
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-under-unified-payer.md:set_created:2026-03-19"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:missing_attribution_extractor"
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-under-unified-payer.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
"date": "2026-03-19"
|
||||
}
|
||||
|
|
@ -7,13 +7,17 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-19
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -55,3 +59,15 @@ EXTRACTION HINT: Focus on the distinction between system-level cost impact (infl
|
|||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074/subject; avoided CV events: $1,512/subject
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare semaglutide modeling projects net savings of $715M over 10 years (range: $412M to $1.04B)
|
||||
- T2D-related semaglutide impact: $892M savings over 10 years
|
||||
- Obesity-related semaglutide impact: $205M added costs over 10 years
|
||||
- MASH-related semaglutide impact: $28M savings over 10 years
|
||||
- 38,950 cardiovascular events avoided over 10 years with comprehensive semaglutide access
|
||||
- 6,180 deaths avoided (CV + CKD/MASH progression)
|
||||
- Average per-subject lifetime semaglutide treatment costs: $47,353
|
||||
- Per-subject savings: $14,431 (T2D), $2,074 (CKD), $1,512 (CV events)
|
||||
- Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
|
|
|
|||
Loading…
Reference in a new issue